Making any protein possible

Engineering fit-for-purpose biotherapeutics

Rooted in protein modeling and structure-guided engineering, our platforms make any protein possible, from cytotoxic anti-tumor biologics to antibody drug conjugates and immuno-oncology therapies.

Building better biologicsTM

Rationally designed. Elegantly simple.

Fully integrated protein engineering technologies that make any protein possible.

Explore Platforms


Build the Best Bispecifics

by creating tailored multifunctional therapeutics that enable enhanced efficacy and new biological approaches for treating diseases

Two is better than one.

Create novel mechanisms of action through unique binding. 

Azymetric™ is the best-in-class platform for therapeutic antibodies that can simultaneously bind to multiple distinct locations on a target or to multiple targets, resulting in unique mechanisms of action not accessible through typical monospecific antibodies. Azymetric™ bispecific antibodies can block multiple signaling pathways, recruit immune cells to tumors, enhance receptor clustering and internalization, and increase tumor-specific targeting.

How We Differ

Enhance efficacy, simply and efficiently 

Azymetric™ antibodies possess the desirable drug-like features of naturally occurring antibodies, including:

  • Long serum half-life and high stability
  • Ability to mediate effector function
  • Low immunogenicity risk

Azymetric™ antibodies are compatible with standard manufacturing processes with high yields and purity.

  • Use conventional antibody purification and manufacturing processes
  • Rapidly screen target and sequence combinations for bispecific activities in the final therapeutic 

How It Works

The core of the Azymetric™ therapeutic platform consists of proprietary amino acid modifications in the heavy and light chains of an antibody that enable the transformation of monospecific (single target) antibodies into bispecific antibodies, which can simultaneously bind to two distinct locations on a target or two targets.

Azymetric™ antibodies are compatible with glyco-engineering and other Fc modifications, including the EFECT™ Platform, to enhance therapeutic activity. 

Unlike many other bispecific platforms, Azymetric™ enables the generation of fully IgG-like antibodies and is compatible with alternative target binding formats (e.g. Fabs, scFvs, and VHHs) and antibody-drug conjugates.


Enhance Therapeutic Response

with a modular suite of proprietary cytotoxins (cell-killing compounds), stable linkers, and conjugation technologies.

A broader window of opportunity.

Deliver potent cell-killing compounds specifically to diseased target cells with optimal safety and efficacy.

ZymeLink™, a next-generation antibody drug conjugate (ADC) platform, is a suite of proprietary cytotoxins (cell-killing compounds), stable linkers, and conjugation technologies. ZymeLink™ is compatible with traditional antibodies, proteins, and the Azymetric™ bispecific antibody platform, creating multifunctional therapeutics designed to overcome the limitations of existing ADCs. 

How We Differ

Develop next-generation antibody drug conjugates with broad therapeutic windows.

ZymeLink™ antibody drug conjugates are designed to:

  • Closely resemble natural antibodies with improved pharmacokinetics, stability, and cytotoxin exposure over alternative ADC technologies
  • Exhibit increased tolerability
  • Demonstrate a broad therapeutic window, a key competitive advantage over existing ADC platforms

How it Works

The ZymeLink ADC platform is designed to combine the specificity of traditional and bispecific antibodies with the strength of potent cytotoxins (cell-killing compounds) to treat cancer and other diseases.

Zymeworks is developing diverse classes of proprietary cytotoxins with potent anti-tumor activity against a broad range of cancer cell types.  Innovative, stable linkers chemically attach cytotoxins to a variety of targeted therapeutics, including traditional antibodies, proteins, and the Azymetric™ bispecific antibody platform. Each linker is tailored to a specific cytotoxin to enable optimal safety and efficacy of the ADC.

Together, the ZymeLink™ ADC platform and Azymetric™ bispecific antibody platform are designed for the development of best-in-class, life-changing medicines for patients


Customize & Optimize Immune Response

using precise antibody Fc modifications that tailor the antibody-mediated immune response

Get the optimal response.

Tailor immune system response for a desired therapeutic effect using the Effector Function Enhancement and Control Technology’s (EFECT™) library of Fc region modifications.

The EFECT™ library includes proprietary mutations to the CH2 domain of the antibody's Fc region to selectively modulate an antibody’s interactions with the Fc-gamma receptors (FcgR) expressed on the surface of immune cells and with a component of the complement pathway (i.e. C1q).

How We Differ

Tailor therapeutic response by directing the activity of recruited immune cells. 

The EFECT™ platform creates antibody modifications that can:

  • Up-regulate activity to enhance immune function
    Enhance antibody-dependent cellular cytotoxicity (ADCC; NK-cell driven) and antibody-dependent cellular phagocytosis (ADCP; macrophage driven) with EFECT antibody variants that selectively increase binding to the FcgRIIIa and/or FcgRIIa receptors
  • Down-regulate activity to suppress auto-immunity
    Inhibit unwanted antibody-mediated auto-immunity by reducing immune responses of B cells with EFECT antibody variants that selectively increase binding to the FcgRIIb receptors
  • Eliminate cytotoxicity 
    Remove binding to all FcgRs and C1q where effector cell-mediated cytotoxicity is undesirable for therapeutic antibodies.


Tumor‑Specific Immune Co‑stimulation

in a single, transferable, conditionally active design

Right Place at the Right Time

With PROgrammed Tumor Engagement & Checkpoint/Co‑stimulation Targeting, the ProTECT™ platform delivers multifunctional tumor‑specific activity while simultaneously enhancing immune modulation through the conditional activity of a natural immunomodulatory pair such as PD‑1/PD‑L1.

Therapeutics utilizing ProTECT™ have limited exposure and activity in normal healthy tissue, avoiding on‑target, off‑tumor toxicities. Once in the tumor microenvironment, proteases cleave and release one half of the functional block. This activates both the targeting antibody and the immunomodulatory function when and where it is needed.

How We Differ

The ProTECT™ platform is the first conditionally‑active antibody technology that simultaneously addresses both ends of the therapeutic window, potentially reducing toxicity and increasing efficacy.

Unique features of ProTECT™

  • Tumor‑specific activity via conditional blocking to reduce systemic toxicities
  • Functional block adds co‑stimulation or checkpoint modulation to enhance efficacy in the tumor
  • Unique geometry enhances T cell bridging with tumor cells
  • Increased avidity and target engagement with multispecific binding
  • Beyond PD‑1/PD‑L1, additional blocking pairs are being used to provide alternative immunomodulatory approaches e.g. CTLA‑4/CD80, CD28/CD80, PD‑L1/CD80, ICOS/ICOSL, CD47/SIRPa
  • Plug‑and‑play: Blocking approach is transferable with minimal engineering to apply to different targets

How it works

  • Therapeutic activity is blocked in normal tissue to avoid on‑target, off‑tumor toxicities and improve pharmacokinetics
  • Antibody is localized to the tumor through tumor associated antigen targeting
  • Tumor‑specific proteases cleave and release the blocking half of the immunomodulatory pair
  • Both the targeting antibody and the remaining immunomodulatory checkpoint inhibitor / co‑stimulator become active
  • The resulting activated multifunctional therapeutic enables immune modulation in concert with antigen binding to enhance potency
  • Overall increase in therapeutic window through selective tumor activity and enhanced potency

PROTECT‑CD3™ Platform Application

Tumor associated antigen (TAA)  arm directs PROTECT-CD3™ activity to tumor Tumor associated antigen (TAA)  arm directs PROTECT‑CD3™ activity to tumor

Tumor microenvironment protease releases PD-L1 moiety of the mask Tumor microenvironment protease releases PD‑L1 moiety of the mask

Activated PROTECT‑CD3™ trispecific redirects T‑cells while blocking PD‑L1 checkpoint modulation Activated PROTECT‑CD3™ trispecific redirects T‑cells while blocking PD‑L1 checkpoint modulation